Ragupathy K, Ferguson M
Department of Oncology, Ninewells Hospital, Dundee, UK.
J Obstet Gynaecol. 2011;31(2):178-9. doi: 10.3109/01443615.2010.539719.
Our study adds to the BRCAness theory that hereditary ovarian cancers with BRCA 1 or 2 mutations show better chemosensitivity when compared with sporadic ovarian cancers.
我们的研究为“BRCAness理论”增添了内容,该理论认为,与散发性卵巢癌相比,携带BRCA 1或2基因突变的遗传性卵巢癌对化疗更敏感。